Nektar Therapeutics Stock Forecast, Price & News

-0.08 (-0.48 %)
(As of 06/23/2021 01:09 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume14,820 shs
Average Volume1.11 million shs
Market Capitalization$3.02 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Nektar Therapeutics logo

About Nektar Therapeutics

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.68 out of 5 stars

Medical Sector

354th out of 2,105 stocks

Pharmaceutical Preparations Industry

164th out of 832 stocks

Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

Is Nektar Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Nektar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View analyst ratings for Nektar Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Nektar Therapeutics?

Wall Street analysts have given Nektar Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nektar Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Nektar Therapeutics

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.04. The biopharmaceutical company had revenue of $23.60 million for the quarter, compared to the consensus estimate of $26.15 million. Nektar Therapeutics had a negative net margin of 340.31% and a negative trailing twelve-month return on equity of 38.12%. Nektar Therapeutics's revenue for the quarter was down 53.4% on a year-over-year basis. During the same period last year, the company earned ($0.78) EPS.
View Nektar Therapeutics' earnings history

How has Nektar Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NKTR shares have increased by 0.7% and is now trading at $16.59.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NKTR?

6 analysts have issued 1-year price targets for Nektar Therapeutics' stock. Their forecasts range from $18.00 to $26.00. On average, they anticipate Nektar Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for Nektar Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the following people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 68, Pay $2.24M)
  • Mr. Gilbert M. Labrucherie, Sr. VP, CFO & COO (Age 49, Pay $1.54M)
  • Mr. Mark A. Wilson, Sr. VP, Gen. Counsel & Sec. (Age 49, Pay $780.49k)
  • Dr. Jonathan Zalevsky, Chief R&D Officer (Age 46, Pay $1.19M)
  • Mr. John P. Northcott, Sr. VP & Chief Commercial Officer (Age 43, Pay $1.16M)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 55)
  • Ms. Jennifer Ruddock, Sr. VP of Strategy & Corp. Affairs
  • Dr. Mary Tagliaferri, Sr. VP & Exec. Clinical Fellow (Age 55)
  • Dr. Brian L. Kotzin, Interim Chief Medical Officer & Head of Devel. (Age 72)
  • Dr. Kevin Brodbeck, Sr. VP of Manufacturing

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics CEO Howard W. Robin on Howard W. Robin has an approval rating of 81% among Nektar Therapeutics' employees.

Who are some of Nektar Therapeutics' key competitors?

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.44%), Primecap Management Co. CA (9.96%), Maverick Capital Ltd. (3.21%), Bellevue Group AG (2.17%), Geode Capital Management LLC (1.28%) and Camber Capital Management LP (1.10%). Company insiders that own Nektar Therapeutics stock include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics

Which institutional investors are selling Nektar Therapeutics stock?

NKTR stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Millennium Management LLC, Goldman Sachs Group Inc., D. E. Shaw & Co. Inc., Camber Capital Management LP, Primecap Management Co. CA, Burleson & Company LLC, and Ergoteles LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Curet Myriam, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Nektar Therapeutics stock?

NKTR stock was purchased by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Duquesne Family Office LLC, BlackRock Inc., Putnam Investments LLC, Hennion & Walsh Asset Management Inc., Blair William & Co. IL, Dimensional Fund Advisors LP, and State of Tennessee Treasury Department.
View insider buying and selling activity for Nektar Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $16.59.

How much money does Nektar Therapeutics make?

Nektar Therapeutics has a market capitalization of $3.02 billion and generates $152.91 million in revenue each year. The biopharmaceutical company earns $-444,440,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

Nektar Therapeutics employs 718 workers across the globe.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

What is Nektar Therapeutics' official website?

The official website for Nektar Therapeutics is

Where are Nektar Therapeutics' headquarters?

Nektar Therapeutics is headquartered at 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]

This page was last updated on 6/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.